This is a preview of subscription content, log in via an institution to check access.
Reference
Scottish Medicines Consortium. SMC advice: adalimumab (Humira); budesonide (Budenofalk); dexamethasone (Ozurdex); entecavir (Baraclude); idelalisib (Zydelig); linagliptin (Trajenta); liraglutide (Victoza); ofatumumab (Arzerra); vedolizumab (Entyvio). Internet Document : 11 May 2015. Available from: URL: http://www.scottishmedicines.org.uk/Home
Rights and permissions
About this article
Cite this article
SMC accepts 9 new treatments. PharmacoEcon Outcomes News 728, 37 (2015). https://doi.org/10.1007/s40274-015-2157-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2157-z